Citation BlueCross BlueShield Association. Special report: vaccines for the treatment of prostate cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 24(6). 2009 Authors' conclusions Other than sipuleucel-T and ProstVAC-VF, other types of vaccines are much less advanced in the types of clinical investigations that have been carried out. These other vaccines still await the initiation and completion of Phase II randomized trials.The prognosis of the current indication of these vaccine products is a median survival between 20 and 30 months. Demonstration of a survival benefit among candidate patients at earlier stages of disease would require much longer periods of study due to the greater baseline prognosis of these patients. However, without such studies, it would be premature to extend the indications for such vaccines (if any are proven to be effective for the current indication). Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents Vacciness; Male; Prostatic Neoplasms Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com AccessionNumber 32011000009 Date abstract record published 19/01/2011 |
